Wall Street Zen Upgrades Amylyx Pharmaceuticals (NASDAQ:AMLX) Stock Rating

Analysts raise stock rating from 'sell' to 'hold' for the biopharmaceutical company focused on rare neurological diseases.

Published on Mar. 9, 2026

Got story updates? Submit your updates here. ›

Amylyx Pharmaceuticals (NASDAQ:AMLX), a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases, has had its stock rating upgraded by analysts at Wall Street Zen from a 'sell' to a 'hold' rating. The upgrade comes as several other brokerages have also weighed in on AMLX, with Stifel Nicolaus and Bank of America issuing 'buy' ratings and price targets.

Why it matters

Amylyx's lead product, AMX0035, was recently approved by the FDA under the trade name Relyvrio, providing a new treatment option for patients with rare neurological conditions. The stock rating upgrade and positive analyst sentiment suggest growing confidence in the company's prospects as it works to bring innovative therapies to market.

The details

In a research report issued to clients and investors, Wall Street Zen analysts upgraded their rating on Amylyx Pharmaceuticals from 'sell' to 'hold'. Other brokerages have also weighed in, with Stifel Nicolaus assuming coverage with a 'buy' rating and $21 price target, and Bank of America boosting its price target from $15 to $19 while maintaining a 'buy' rating.

  • The rating upgrade from Wall Street Zen was issued on Saturday, March 9, 2026.
  • Stifel Nicolaus assumed coverage on Amylyx on Tuesday, March 3, 2026.
  • Bank of America updated its price target and rating on Amylyx on Friday, February 20, 2026.

The players

Amylyx Pharmaceuticals

A biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases, founded in 2013 and headquartered in Cambridge, Massachusetts.

Wall Street Zen

An equity research firm that provides analysis and ratings on publicly traded companies.

Stifel Nicolaus

A full-service wealth management and investment banking firm.

Bank of America

A multinational investment bank and financial services company.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee (Instagram)

What’s next

The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.

The takeaway

This case highlights growing concerns in the community about repeat offenders released on bail, raising questions about bail reform, public safety on SF streets, and if any special laws to govern autonomous vehicles in residential and commercial areas.